STOP TERAPIA NUCLEOT(S)IDI NELL’EPATITE CRONICA HBeAg-NEGATIVA: OCCHIO AI RISCHI ! UN’OTTIMA META-ANALISI DA GUT

Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis Samuel Anthony Lachlan Hall et al. Abstract Background and aims Sustained virological suppression and hepatitis B surface antigen (HBsAg) loss have been described after nucleot(s)ide analogue (NA) discontinuation for patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB). We performed a meta-analysis…

UN PORTALE PER “BUCARE” IL MURO DEL PAGAMENTO ED ARRIVARE ALLE PUBBLICAZIONI. DA QxMD

A portal to the papers beyond paywalls QxMD Bets are a paywall has stopped you from reading a paper at some point. Maybe that paper would have influenced your clinical practice? Saved a life? That might be a stretch, but there is significant evidence to suggest papers behind paywalls are viewed less and have less…

LA GRANDE STORIA DEI VACCINI A mRNA DA NATURE

The tangled history of mRNA vaccines Hundreds of scientists had worked on mRNA vaccines for decades before the coronavirus pandemic brought a breakthrough. Elie Dolgin   In late 1987, Robert Malone performed a landmark experiment. He mixed strands of messenger RNA with droplets of fat, to create a kind of molecular stew. Human cells bathed…

ODDS VS PROBABILITA’ : UN MINUTO PER COMPRENDERE LA DIFFERENZA E PASSARE DALL’UNO ALL’ALTRA !

Odds != Probability Keith McNulty (Expert and Author in Applied Mathematics, Data Science, Statistics and Psychometrics. Find me on LinkedIn or Twitter or drkeithmcnulty.com) Many people use the words ‘odds’ and ‘probability’ interchangeably. They are both terms that imply an estimate of likelihood or chance. I can understand this for laypeople, but I often see…

CARCINOMA EPATOCELLULARE: UNA REVISIONE ED UNA META-ANALISI DI GASTROENTEROLOGY SUI TRIAL DELL’ULTIMO VENTENNIO

Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002–2020) Philipp K. Haber et al. Background & Aims Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with a rapidly changing landscape of treatments. In the past 20 years, numerous randomized controlled trials (RCTs) have aimed at improving outcomes across…

IPERTENSIONE PORTALE ED ASCITE. LE NUOVE LINEE GUIDA AISF EVIDENCE-BASED (PICO QUESTION) !

Portal Hypertension and Ascites: Patient-and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (AISF) Portal hypertension and ascites are two crucial events in the natural history of liver cirrhosis, whose appearance marks a downward shift in the prognosis of the disease. Over the years, several international and national societies…